Free tool
Oncology stocks
We cover 9 companies grouped under the Oncology theme. The median market value in the group is $28.28B. Across the group, the median move over the past trading day is −1.09%. Price change over the past year runs from −4.5% to +134.1% across the middle 80 percent of the group, with a median of +36.2%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
9 of 319 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return |
|---|---|---|---|---|
| AZN | AstraZeneca PLC | $263.12B | Mega cap | +5.09% |
| BMY | Bristol-Myers Squibb Company | $138.03B | Large cap | +47.01% |
| RVMD | Revolution Medicines, Inc. | $46.18B | Large cap | +466.35% |
| ONC | BeOne Medicines AG | $42.58B | Large cap | +25.21% |
| BNTX | BioNTech SE | $28.28B | Large cap | +9.27% |
| INCY | Incyte Corporation | $25.97B | Large cap | +51.01% |
| GMAB | Genmab A/S | $21.42B | Large cap | +36.20% |
| EXEL | Exelixis, Inc. | $14.05B | Large cap | +45.68% |
| SMMT | Summit Therapeutics Inc. | $11.35B | Large cap | −42.63% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.